Breast cancer is the second commonest primary tumour responsible for gastrointestinal metastases after malignant melanoma. The real incidence of gastrointestinal metastases in breast cancer patients is probably underestimated owing to the non-specific presenting symptoms and death of patients caused by other more obvious metastases. The predominant histological subtype of gastrointestinal metastases of breast cancer is invasive lobular carcinoma and the median interval from diagnosis of primary breast cancer to gastrointestinal metastases is five years. We report two cases of disseminated breast cancer with gastrointestinal involvement with a rather long survival.
Introduction
In Western countries breast cancer is the commonest female cancer and the leading cause of death among women, in the fourth and fifth decade of life. Prognosis depends on tumour size, histological subtype, hormonal receptors and invasion of axillary lymph nodes.
The most common histological subtype is invasive ductal carcinoma, followed by lobular, medullary, tubular and mucinous carcinoma [1] . Approximately 50% of the patients with breast cancer will develop distant metastases during their life time, although autopsy data report a higher incidence of subclinical distant metastases. The most frequent locations of distant involvement are lymph nodes, bone, lung and liver. Less common sites of metastases are skin, brain and gastrointestinal tract [2, 3] . The real incidence of gastrointestinal metastases in breast cancer patients is probably underestimated. Non-specific presenting symptoms and the death of patients caused by other more obvious metastases are responsible for this [4] . However, during the last 30 years more than 1000 cases of gastrointestinal metastases from breast cancer have been reported [5] . In only 6% of patients with breast cancer are gastric metastases detected during their life time. Whereas, autopsy data report a frequency of about 8%-15% in patients dying of disseminated breast cancer. The same frequency is found for colorectal metastases [2, 3, [5] [6] [7] . The predominant histological subtype of gastrointestinal metastases from a primary breast cancer is invasive lobular carcinoma. The most common type of involvement of gastrointestinal organs is a diffuse intramural infiltration, mimicking linitis plastica of the stomach. Microscopic examination frequently shows an infiltration of normal tissue by cancer cells, arrayed in 'Indian file'cords [6] [7] [8] [9] . The median interval from diagnosis of primary breast cancer to appearance of gastric as well as of colorectal metastases is four to five years. Coexisting metastases in other tissues are present in up to 90% of cases [6, 7] .
Differentiation from a benign gastric lesion (leiomyoma, polyp, etc.), solitary gastric ulcer, primary gastric cancer, Crohn's disease and lymphoma is often difficult [6, 7, 15, 16] . Once the diagnosis of gastrointestinal metastases is made, the median survival of patients is about one year [6, 7] . Long-term survival is rare. Diagnosis of gastrointestinal metastases is difficult. Radiography, with barium or water-soluble contrast material, conventional ultrasound, endoscopy with deep biopsy and echoendoscopy can help make the final diagnosis. However, an endoscopic biopsy can be negative in more than 50% of cases [5, 6] . This is probably because the intramural lesion is inaccessible to the biopsy forceps. In addition, histological examination of the surgical specimen often reveals involvement of the serosal, muscular and submuscular layers, whereas the mucosa is normal.
Surgical treatment, often palliative, should be reserved for patients with isolated lesions, emergencies (perforation, obstruction and hemorrhage) and in patients where tumour debulking could improve the effect of chemotherapy. If, in addition to gastrointestinal metastases, metastases at other sites are present and/or the condition of the patient is not favourable, other treatment modalities (hormones, chemo-and radiotherapy) may be indicated depending on prior therapy. If a non-surgical treatment is applied, the overall response rate in breast cancer patients with gastric metastases is 32% and 53% in patients with colorectal metastases [6, 7] . The main causes of death among patients with known gastrointestinal metastases are gastrointestinal obstruction, perforation, septic shock and total renal failure.
We report two cases of disseminated breast cancer with gastrointestinal involvement with a rather long sur-vival, one of them still being disease free five years after diagnosis.
Casel
The first patient was treated at the age of 58 year for a lobular carcinoma of the left breast, clinical stage T 2 N o M x , with a modified radical mastectomy and postoperative radiotherapy. The final stage was pT 2 N lb M 0 with four out of 11 axillary lymph nodes involved. She received adjuvant tamoxifen, 20 mg daily, for five years. Estrogen-(ER) and progesterone receptors (PR) in the primary tumour were determined by immunohistochemistry (ERICA and PRICA) and were negative. Ten years after primary treatment she presented with anorexia, epigastric pain and dysphagia. Endoscopy revealed thickened erythematous mucosal folds in the corpus of the stomach. Three out of 10 biopsies were positive for metastatic breast carcinoma. Abdominal ultrasound and computerised tomography (CT scan) showed diffuse tumour infiltration of the anterior gastric wall. Additional imaging techniques did not reveal other distant metastases at that time. An exploratory laparotomy was performed and confirmed gastrointestinal involvement: total gastrectomy, omentectomy, splenectomy and partial resection of the transverse colon and tail of the pancreas were carried out. Histology revealed a linitis plastica-like infiltration with involvement of the whole corpus of the stomach, lymph node involvement along the vessels of the spleen and invasion of the transverse mesocolon. Resection margins were free of tumour. Immunohistochemical staining revealed moderate positivity for ER and PR and the cytoplasm of the metastatic cells stained positive for carcinoembryonic antigen (CEA). Eighteen months postoperatively, hormonal treatment with tamoxifen, 40 mg daily, was given. Within six months this resulted in a significant decrease of the pre-tamoxifen level of the tumour marker CA 549, from 145 U/ml to 38 U/ml (normal values: 0-10 U/ml). From that time on no further changes in the CA 549 level occurred. Now, at 73 years of age, she is still free of disease five years after the diagnosis of gastrointestinal metastases, and is still on tamoxifen treatment.
Case 2
A 56-year-old woman was treated with a modified radical mastectomy for a carcinoma in the left breast, clinical stage T 2 N o M x . Histology revealed an invasive lobular carcinoma and no lymph nodes were invaded. The final stage was pT 2 N o M o . She received no adjuvant therapy. Five years later, at the age of 61 years, she developed a contralateral breast carcinoma, clinical stage T] C N o M x . Again a modified radical mastectomy was performed. Histology revealed an invasive ductal carcinoma. Again, she received no adjuvant therapy. Thirteen years after the diagnosis of the primary tumour and eight years after the second tumour she developed bone metastases. Hormonal treatment with tamoxifen was initiated. One year later she complained of painful breathing, coughing, abdominal pain, anorexia and febrile periods. Chest X-ray showed evidence of a pleuritic reaction with pleural effusion. Cytological examination of the pleural aspiration showed malignant cells, supporting the diagnosis of carcinomatous involvement of the pleura. Endoscopy of the stomach showed localised thickening of intact mucosal folds without ulcerations. No biopsy was performed. Abdominal ultrasound revealed a moderate amount of ascites and a localised thickening of the anterior part of the stomach. Because of the pleural infiltration with tumour, chemotherapy with Methotrexate, Mitomycin C and Mitoxantrone was started. Eight months later the patient was in complete remission, as seen on chest X-ray (no signs of pleural involvement) and abdominal ultrasound (no ascites), with normalisation of the tumour marker CA 15.3. Hormonal treatment with medroxyprogesterone acetate, 500 mg daily, was given after discontinuation of chemotherapy. Ten months later progression of disease was seen and a third line hormonal treatment with aminogluthetimide (500 mg/day) was started, without response. Two months later she again developed symptoms of carcinomatous pleural effusion. Aspirations of the pleura fluid were needed. Chemotherapy with cyclophosphamide, methotrexate and fluorouracil was given. Three months later she was admitted to the hospital because of deterioration of her general condition. CT scanning of the chest showed a hydropneumothorax and metastases on the visceral pleura. A thoracic drain was placed and chemical pleurodesis with tetracyclines was performed. Gastroscopy again revealed thickened erythematous mucosal folds of the whole stomach wall. Biopsy confirmed diffuse intramural infiltration by breast cancer cells arrayed in cords, typical of invasive lobular carcinoma. Abdominal ultrasound and CTscan of the abdomen confirmed diffuse infiltration of the stomach. A third-line chemotherapy with adriamycin and VP16 was started. One month later she showed a remarkable clinical improvement of her general condition. Five months later she developed headache, dizziness, febrile periods, nausea and vomiting, anorexia, painful breathing, weakness in the legs and pain at the thoracic vertebral column. Bone scan with Technetium showed progression of the bone metastases. Magnetic resonance imaging (MRI) of the brain and meninges was normal. Examination of cerebrospinal fluid revealed no metastatic cells. A palliative treatment with corticosteroids and hormonal replacement therapy was started. She died from total renal failure one month later, at the age of 72 years, 16 years after the diagnosis of the primary tumour and 22 months after the first clinical symptoms of gastric involvement, confirmed also at autopsy.
Discussion
Breast cancer is the second commonest primary tumour responsible for gastrointestinal metastases after malig-nant melanoma [5] [6] [7] 10] . Reports of metastases of breast cancer to colon and other organs such as pituitary gland are sparse [11] [12] [13] [14] .
The two cases reported here confirm the long interval between diagnosis of primary breast cancer and the first clinical manifestation of gastrointestinal metastasis, respectively 10 and 14 years. The diagnosis in both patients was initially supported by non-invasive techniques: abdominal ultrasound and CTscan of the abdomen. These techniques showed an abnormal thickness of the gastric wall and diffuse intramural infiltration, typical for linitis plastica. After endoscopy and biopsy, histological diagnosis of gastric involvement in the first case was made at the initial presentation of symptoms, whereas in the second case histological diagnosis was made probably at a more advanced stage of the disease. The remarkable survival in the first case is probably due to the absence of other distant metastases and early surgical treatment. The second patient developed gastric metastasis after a disease free survival of 14 years, but other sites of involvement were also found. During the 22 months after the initial symptoms of gastric involvement, she received several types of chemotherapy, with temporarily remissions.
Clinical manifestations of gastrointestinal metastases are usually non-specific. Abdominal pain and persistent gastric disorders in patients affected by breast cancer warrants further investigations in an early attempt to document any possible gastrointestinal metastasis. The diagnosis is usually made by endoscopy with biopsy and radiography, but is frequently not conclusive. However, it is important to confirm suggestive findings of gastric involvement, identified on ultrasound, radiography or CT scan, with endoscopy and biopsy. Ultrasound and CT scan of the abdomen were in both cases useful and good alternative techniques because of their non-invasive character and because they gave additional information to the endoscopic findings. Radiography with barium or water-soluble material was not considered as a diagnostic procedure. Typical radiographic features are described but are also seen in Crohn's disease [15, 16] .
Histology of the stomach shows a diffuse intramural infiltration of the gastric wall, with the typical pattern of spread for invasive lobular carcinoma: small cells with monomorphic, round nuclei and vacuolated cytoplasm, diffusely arrayed in 'Indian file' cords throughout the tissue. The metastatic process involves the serosal, muscular and submucosal layer, whereas the mucosa is often normal. Dissemination occurs by the lymphatic pathway, mesenteric reflections, intraperitoneal seeding and embolic metastases [6, 7] .
Once the diagnosis of gastrointestinal metastases is made median survival is approximately one year. The late clinical manifestations and diagnosis of gastric involvement add to this poor prognosis. Important prognostic factors are other distant sites of metastasis and local spread of the tumour.
The overall response rate to non-surgical treatment (hormones, chemo-and radiotherapy) is in case of gastric or colorectal involvement respectively 32% and 53% [6, 7] . Surgical treatment, usually palliative, is only indicated in selected cases and is rarely an emergency. Hormone-and chemotherapy are appropriate in most situations. Surgery may be needed, especially when gastrointestinal involvement is the only distant site of metastasis or when severe complications (perforation, obstruction or hemorrhage) occur. However, at the time of diagnosis of gastrointestinal metastases it is difficult to exclude other distant (micro)metastases. In some selected patients with favourable general condition exploratory laparotomy with tumour debulking can be useful.
